10,160 reports of this reaction
3.6% of all CYCLOPHOSPHAMIDE reports
#3 most reported adverse reaction
NEUTROPENIA is the #3 most commonly reported adverse reaction for CYCLOPHOSPHAMIDE, manufactured by Avyxa Pharma, LLC. There are 10,160 FDA adverse event reports linking CYCLOPHOSPHAMIDE to NEUTROPENIA. This represents approximately 3.6% of all 284,202 adverse event reports for this drug.
Patients taking CYCLOPHOSPHAMIDE who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among CYCLOPHOSPHAMIDE users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for CYCLOPHOSPHAMIDE:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 10,160 FDA reports for CYCLOPHOSPHAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.6% of all adverse event reports for CYCLOPHOSPHAMIDE, making it one of the most commonly reported side effect.
If you experience neutropenia while taking CYCLOPHOSPHAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.